TRDA
Entrada Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 26 ▼ Entrada Therapeutics reported financial results for Q4 and full year…
- Mar 10 ▼ 2 insiders sell $303.4K at $13.03
- Apr 1 ▼ 1 insider sell $32.4K at $12.95
- May 4 ▼ 2 insiders sell $628.8K at $15.37
- May 7 Entrada Therapeutics reported Q1 2026 results with a net loss of $39…
- May 20 ▲ 1 insider buy $29.3K at $5.86
- Jun 2 FDA: Independent Safety Data Monitoring Committee Recommends In…
- Jul 30 to Aug 10 ▼ 5 days of insider sells: $3.1M by 2 insiders, avg $6.93
- Aug 24 to Sep 9 ▼ 12 days of insider sells: $7.2M by 2 insiders, avg $7.26
- Sep 9 ▼ Two MPM BioVentures funds (10% owners) sold a combined $547K in TRDA…
- Oct 14 ▲ Entrada Therapeutics announced positive topline data from Cohort 1 o…
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $29.3K at an average $5.86. 7 insiders sold $11.3M. Price is 15% below their cost.
- InstitutionsBULLISH
Q3 2026: 24 added (0 new), 8 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$0.873 → −$1.060 over 90 days. 1 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest −14.2% to 2.81M shares. 6.9 days to cover, ≈7.2% of shares.
- TrendDOWNTREND
10% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $20.6M |
| UBS Group AG | DOUBLED | $4.0M |
| MORGAN STANLEY | DOUBLED | $2.5M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $1.5M |
| Qube Research & Technologies Ltd | DOUBLED | $953.9K |
| Jump Financial, LLC | DOUBLED | $522.3K |
| BARCLAYS PLC | DOUBLED | $448.5K |
| RHUMBLINE ADVISERS | ADD | $349.6K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Jun 2026Price is below the lowest target. Median implies +300%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Jun 8, 2026 | Guggenheim MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
MPM BioVentures 2014, L.P. 10%+ Owner Sep 9, 2026 | SELL | $205.6K |
MPM BIOVENTURES 2018, L.P. 10%+ Owner Sep 9, 2026 | SELL | $205.6K |
MPM BioVentures 2014, L.P. 10%+ Owner Sep 8, 2026 | SELL | $1.4M |
MPM BIOVENTURES 2018, L.P. 10%+ Owner Sep 8, 2026 | SELL | $1.4M |
MPM BioVentures 2014, L.P. 10%+ Owner Sep 4, 2026 | SELL | $273.7K |
MPM BIOVENTURES 2018, L.P. 10%+ Owner Sep 4, 2026 | SELL | $273.7K |
MPM BIOVENTURES 2018, L.P. 10%+ Owner Sep 3, 2026 | SELL | $231.3K |
MPM BioVentures 2014, L.P. 10%+ Owner Sep 3, 2026 | SELL | $231.3K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.06 | -$1.15–-$0.96 | -20.1% | $1.4M |
| Next Q | -$0.76 | -$1.10–-$0.12 | +0.7% | $18.3M |
| Current FY | -$3.96 | -$4.05–-$3.86 | -4.4% | $4.0M |
| Next FY | -$3.40 | -$4.16–-$2.90 | -12.9% | $20.4M |
Short side
FINRA· Oct 30, 2026SecBot reports
20 filings · 1 press release · 1 bullish · 4 bearish · 1 mixed · 14 neutral- NEUTRAL 8-KNov 5, 2026
The company highlighted positive safety data from ELEVATE-45-201 Cohort 1 and progress across its…
Monitor upcoming clinical catalysts: ELEVATE-44-201 Cohort 1 open-label data by year-end 2026, Cohort 2 data in Q1 2027, and Vertex's VX-670 interim results in H2 2026. Cash runway into Q4 2027…
- NEUTRAL PRESS-RELEASENov 5, 2026
Entrada Therapeutics reported Q3 2026 net loss of $39.7M ($0.94 per share), narrower than the…
The EPS beat and cash runway extension are modest positives, but the company remains pre-revenue with significant cash burn. Key catalysts are the upcoming ELEVATE-44-201 Cohort 1 open-label data…
- BULLISH 8-KOct 14, 2026
Entrada Therapeutics announced positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-45-201…
Cohort 1 data de-risks the safety profile at the starting dose and provides proof-of-mechanism with dystrophin production. The key catalyst is Cohort 2 data in H1 2027 at 2x the dose, where the…
- BEARISH CLUSTERSep 9, 2026
Two MPM BioVentures funds (10% owners) sold a combined $547K in TRDA shares over two days, part of…
The largest shareholder group is systematically reducing its stake with no insider buying to counterbalance. Monitor for additional MPM sales in coming weeks and any catalyst that might explain the…
All TRDA filing & press-release reports (21)
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- 8-K reportOct 14, 2026
- CLUSTER reportSep 9, 2026
- CLUSTER reportSep 3, 2026
- CLUSTER reportAug 31, 2026
- CLUSTER reportAug 31, 2026
- CLUSTER reportAug 31, 2026
- CLUSTER reportAug 26, 2026
- CLUSTER reportAug 10, 2026
- 8-K reportAug 5, 2026
- CLUSTER reportAug 3, 2026
- 144 reportJul 30, 2026
- 8-K reportJun 10, 2026
- PRESS-RELEASE reportJun 2, 2026
- PRESS-RELEASE reportMay 7, 2026
- CLUSTER reportMay 4, 2026
- 144 reportMay 4, 2026
- DEFA14A reportApr 24, 2026
- CLUSTER reportMar 4, 2026
- 8-K reportFeb 26, 2026